SMMT: Summit Therapeutics is a Sell
The current rating for SMMT is 42, which is
its historic median rating of 50. This indicates higher risk than normal.
The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.